Evidence map›Paper›PMID 41584607›Full record

ArticleFrontiers in oncology2025

Global comparison of breast cancer burden between women aged 20-54 and ≥55 years (1990-2021).

Xingxin Ouyang, Hao Liu, Huimin Jin

Abstract read
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xingxin Ouyang *Department of Breast Surgery, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University/Hunan Cancer Hospital, Changsha, China.
Hao Liu *Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.
Huimin JinDepartment of General Surgery, The Second Xiangya Hospital, Central South University, Changsha, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: While the global burden of breast cancer continues to rise, comparative long-term trends in incidence and mortality between reproductive-age and older women remain inadequately characterized across different socio-demographic settings. Methods: Data on female breast cancer incidence, mortality, and disability-adjusted life years (DALYs) from 1990 to 2021 were obtained from the Global Burden of Disease 2021 study. Trends were analyzed for two age groups (20-54 and ≥55 years). The Estimated Annual Percentage Change (EAPC) was calculated using joinpoint regression, which identifies significant trend changes by fitting a series of linear segments connected at "joinpoints."Statistical comparisons of trends between age groups and SDI regions were conducted using t-tests based on the Joinpoint software framework. Results: Between 1990 and 2021, global breast cancer incidence increased in both age groups, with a more pronounced rise among women aged 20-54 years. Mortality and DALYs diverged: both increased in younger women but declined in those aged ≥55 years. Geographic disparities were strongly linked to SDI levels; although high-SDI regions reported higher incidence, they also showed steeper recent mortality reductions, highlighting the roles of risk factor profiles and healthcare access. Conclusion: This study offers a novel, age-stratified comparison of global breast cancer burden across SDI regions over three decades. Our findings underscore the necessity of age-specific and resource-stratified strategies for prevention and control to mitigate the growing burden in both younger and older women.

Indexed as

breast cancerdisease burdenEAPCepidemiologyGBD database

Identifiers

PMID41584607
PMCPMC12823880

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.